Inspire Medical Systems, Inc. (NYSE:INSP) Position Boosted by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. lifted its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 18.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,382 shares of the company’s stock after purchasing an additional 533 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Inspire Medical Systems were worth $688,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of INSP. Altshuler Shaham Ltd acquired a new stake in Inspire Medical Systems during the fourth quarter worth about $29,000. NBC Securities Inc. acquired a new stake in Inspire Medical Systems during the third quarter worth about $34,000. Parkside Financial Bank & Trust acquired a new stake in Inspire Medical Systems during the first quarter worth about $37,000. Meeder Asset Management Inc. raised its stake in Inspire Medical Systems by 7,850.0% during the fourth quarter. Meeder Asset Management Inc. now owns 159 shares of the company’s stock worth $40,000 after acquiring an additional 157 shares during the period. Finally, Arcadia Investment Management Corp MI raised its stake in Inspire Medical Systems by 44.5% during the third quarter. Arcadia Investment Management Corp MI now owns 224 shares of the company’s stock worth $44,000 after acquiring an additional 69 shares during the period. Institutional investors and hedge funds own 94.91% of the company’s stock.

Insider Buying and Selling

In related news, insider Randy Ban sold 3,060 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $182.01, for a total transaction of $556,950.60. Following the completion of the sale, the insider now directly owns 3,029 shares in the company, valued at $551,308.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Randy Ban sold 3,060 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $182.01, for a total transaction of $556,950.60. Following the completion of the sale, the insider now directly owns 3,029 shares in the company, valued at $551,308.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jerry C. Griffin sold 554 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $193.53, for a total transaction of $107,215.62. Following the sale, the director now owns 10,190 shares of the company’s stock, valued at $1,972,070.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,371 shares of company stock worth $12,213,828. Corporate insiders own 4.10% of the company’s stock.

Inspire Medical Systems Price Performance

NYSE INSP opened at $243.51 on Thursday. Inspire Medical Systems, Inc. has a 12 month low of $123.27 and a 12 month high of $330.00. The firm has a market capitalization of $7.38 billion, a PE ratio of -329.07 and a beta of 1.37. The company’s 50 day simple moving average is $202.06 and its 200 day simple moving average is $183.36.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.53. The business had revenue of $192.51 million for the quarter, compared to analyst estimates of $186.75 million. Inspire Medical Systems had a negative net margin of 3.39% and a negative return on equity of 3.93%. The business’s revenue for the quarter was up 39.6% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. Sell-side analysts anticipate that Inspire Medical Systems, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on INSP. Morgan Stanley began coverage on shares of Inspire Medical Systems in a research note on Tuesday, March 19th. They issued an “overweight” rating and a $250.00 price target on the stock. Truist Financial restated a “buy” rating and issued a $280.00 price target on shares of Inspire Medical Systems in a research note on Wednesday, March 20th. Mizuho restated a “buy” rating and issued a $250.00 price target on shares of Inspire Medical Systems in a research note on Wednesday, March 27th. Stifel Nicolaus restated a “hold” rating and issued a $210.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, January 2nd. Finally, KeyCorp began coverage on shares of Inspire Medical Systems in a research note on Tuesday, February 6th. They issued an “overweight” rating and a $278.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $271.29.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.